References
- Basudan AM. The Role of Immune Checkpoint Inhibitors in Cancer Therapy. Clin Pract. 2022; 13(1): 22-40.
- Husebye ES, Castinetti F, Criseno S, et al. Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. Eur J Endocrinol. 2022; 187(6): G1-G21.
- Castinetti F, Borson-Chazot F. Introduction to expert opinion on endocrine complications of new anticancer therapies. Ann Endocrinol (Paris) 2018; 79:535-8.
- Byun DJ, Wolchok JD, Rosenberg LM, et al. Cancer immunotherapy – immune checkpoint blockade and associated endo crinopathies. Nat Rev Endocrinol 2017; 13:195–207.
- Lugowska I, Teterycz P, Rutkowski P. Immunotherapy of melanoma. Contemp Oncol (Pozn) 2018; 22:61–7.
- González-Rodríguez E, Rodríguez-Abreu D, Spanish Group for Cancer Immuno-Biotherapy (GETICA). Immune check-point inhibitors: review and management of endocrine adverse events. Oncologist 2016; 21:804–16.
- Ibrahim R, Saleh K, Chahine C et al. LAG-3 Inhibitors: Novel Immune Checkpoint Inhibitors Changing the Landscape of Immunotherapy. Biomedicines. 2023; 11(7):1878.
- Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncology. 2018; 4: 1721–1728.
- Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 2018; 4:173–82.
- Elantably D, AI Armashi AR, Hammad F, et al. Immune check-point inhibitor-related endocrinopathies: A nationwide population-based study. JCO 2022, 40: 2653-2653.
- de Filette J, Andreescu CE, Cools F, et al. A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Horm Metab Res 2019; 51:145–56.
- Bai X, Chen X, Wu X, et al. Immune checkpoint inhibitor-associated thyroid dysfunction: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase. European Journal of Endocrinology. 2020; 182:1–9.
- Stelmachowska-Banas M, Czajka-Oraniec I. Management of endocrine immune-related adverse events of immune check-point inhibitors: an updated review. Endocrine Connections. 2020; 9: R207–R228.
- Iyer PC, Cabanillas ME, Waguespack SG et al. Immune-related thyroiditis with immune checkpoint inhibitors. Thyroid. 2018; 28: 1243–1251
- Brancatella A, Viola N, Brogioni S, et al. Graves’ disease induced by immune checkpoint inhibitors: a case report and review of the literature. European Thyroid Journal. 2019; 8:192–195.
- Sagiv O, Kandl TJ, Thakar SD, et al. Extraocular muscle enlargement and thyroid eye disease-like orbital inflammation associated with immune checkpoint inhibitor therapy in cancer patients. Ophthalmic Plastic and Reconstructive Surgery. 2019; 35: 50–52.
- Yuen K, Samson S, Bancos I, et al. American Association of Clinical Endocrinology Disease State Clinical Review: Evaluation and Management of Immune Checkpoint Inhibitor-Mediated Endocrinopathies: A Practical Case-Based Clinical Approach. Endocrine Practice. 2022; 28(7): 719-731.
- Li X, Song Z, Chen Y, et al. Immune checkpoint inhibitors-related thyroid dysfunction: influencing factor analysis, prediction model development, and management strategy proposal. Cancer Immunol Immunother 2025, 74 (2).
- Lu D, Yao J, Yuan G, et al. Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System. Oncologist. 2022;27(2):e126-e132.
- Kennedy OJ, Ali N, Lee R, et al. Thyroid dysfunction after immune checkpoint inhibitors in a single-centre UK pan-cancer cohort: A retrospective study. European Journal of Cancer, 2024; 202, 113949.
- Karaviti D, Kani ER, Karaviti E, et al. Thyroid disorders induced by immune checkpoint inhibitors. Endocrine. 2024; 85(1):67-79.